Antibiotics and psilocybin.
23 records in this group. None has published human data with psilocybin or another classic psychedelic; the rest draw on each medication's own pharmacology and label. State rules are summarized for Colorado, Oregon and New Mexico.
Also searched as antibiotic
01 What the evidence covers
Best evidence available per medication| 23 | No psilocybin data No psilocybin data: no human data with psilocybin or another classic psychedelic; the text draws on the medication's own pharmacology and its label or reference facts |
02 Each medication
A to ZEar, nose and throat infections; Urinary and genital tract infections
Not studied with psilocybin; no linking mechanism is described.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Lower respiratory tract infections; Ear infections (otitis media)
Not studied with psilocybin; no linking mechanism is described. Also, its label warns of liver problems.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Respiratory infections (bacterial COPD flare-ups, sinusitis, pneumonia); Strep throat and tonsillitis
Any interaction with psilocybin is theoretical. Also, it can affect heart rhythm, more so alongside other drugs with that effect.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Community-acquired pneumonia; Bronchitis flare-ups (acute exacerbations of chronic bronchitis)
Not studied with psilocybin; no linking mechanism is described.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
- CefuroximeEvidence: No psilocybin data
Pharyngitis/tonsillitis; Acute bacterial otitis media
Not studied with psilocybin; no linking mechanism is described.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Respiratory tract infections; Middle ear infection (otitis media)
Not studied with psilocybin; no linking mechanism is described.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Skin infections; Bone and joint infections
Not studied with psilocybin; its rare hallucinations and psychotic reactions can overlap psilocybin's effects. Also, it can affect heart rhythm and raise seizure risk.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
- ClarithromycinEvidence: No psilocybin data
Respiratory tract infections (bronchitis flares, sinusitis, community-acquired pneumonia, strep throat); Uncomplicated skin infections
It may slow how the body clears psilocybin by blocking an enzyme. Also, it can affect heart rhythm, and its label lists liver injury.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Serious respiratory tract infections; Serious skin and soft tissue infections
Not studied with psilocybin; no linking mechanism is described.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Rickettsial infections (e.g., Rocky Mountain spotted fever); Sexually transmitted infections (e.g., chlamydia, gonorrhea, syphilis)
Not studied with psilocybin; no linking mechanism is described.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Respiratory tract infections (including Legionnaires' disease); Skin and soft tissue infections
It may somewhat slow how the body clears psilocybin. Also, it can cause heart-rhythm (QT) effects, more so with similar drugs.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
- IsoniazidEvidence: No psilocybin data
Tuberculosis (all forms, with other antituberculosis drugs); Preventive therapy for tuberculosis infection in higher-risk groups
Its label reports some MAO (an enzyme) inhibiting activity, so it may alter how the body clears psilocybin. Also, it can cause severe hepatitis.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Pneumonia (hospital- and community-acquired); Skin and skin structure infections
Not studied with psilocybin. Also, it can cause psychosis or hallucinations from the first dose and affects heart rhythm, seizure threshold and blood sugar.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Pneumonia (hospital- and community-acquired); Skin and skin structure infections (including diabetic foot infections)
It weakly blocks MAO (an enzyme), so it may alter how the body clears psilocybin; its label warns of serotonin syndrome with serotonin-boosting drugs.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Trichomoniasis; Amebiasis (intestinal and liver abscess)
Not studied with psilocybin; no linking mechanism is described. Also, its label reports seizures and nerve effects.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Community-acquired pneumonia; Skin and skin structure infections
Not studied with psilocybin; its boxed warning covers seizures, anxiety, confusion, hallucinations and paranoia. Also, it can change heart rhythm.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Uncomplicated bladder infection (acute cystitis) from susceptible bacteria
Not studied with psilocybin; no linking mechanism is described. Also, it is a common cause of drug-related liver disease.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Bacterial conjunctivitis (pink eye); Bacterial corneal ulcers
Not studied with psilocybin; these eye drops barely reach the body. Also, oral drugs in this class can change heart rhythm.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
- Penicillin VEvidence: No psilocybin data
Mild to moderate streptococcal infections (including strep throat, scarlet fever); Mild to moderate pneumococcal respiratory infections
Not studied with psilocybin; no linking mechanism is described.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
- RifabutinEvidence: No psilocybin data
Prevention of disseminated Mycobacterium avium complex (MAC) disease in advanced HIV infection
Not studied with psilocybin; it speeds an enzyme with a minor role in clearing psilocybin, so slightly weaker effects are possible.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Tuberculosis (all forms, with other drugs); Meningococcal carriers without symptoms (to eliminate Neisseria meningitidis from the nasopharynx)
Not studied with psilocybin; it speeds the enzymes that clear psilocybin, so weaker or shorter effects are possible. Also, its label warns of liver injury.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Urinary tract infections; Middle ear infection (acute otitis media) in children
Not studied with psilocybin; no linking mechanism is described. Also, it rarely lowers blood sugar, and hallucinations are a listed side effect.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Trichomoniasis; Giardiasis
Not studied with psilocybin. Also, its label reports seizures and a reaction with alcohol up to 3 days after the last dose.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
03 Properties the records flag
Records with each flag| 8 | Liver injury |
| 6 | Lowers seizure threshold or carries seizure risk |
| 6 | QT-prolonging |
| 5 | Hypoglycemia risk |
| 4 | Psychiatric reactions |
| 2 | MAO inhibition |
| 2 | Speeds up drug metabolism |
| 1 | Raises blood pressure or heart rate |
| 1 | Serotonergic |
Flags describe a medication's own properties, each cited in its record. A flag is not a finding about any combination. Definitions are on the Method page.
04 State rules
Official text governsNo provision names these medications or this group.
No provision names these medications or this group.
Rules not final; the proposed rules reviewed name no medication in this group.
05 Studies cited in this group
Records citing eachRelated classes
- MAO inhibitors2 shared
Records reviewed 2026-09-30 to 2026-10-14. Each row summarizes one record; the full record, with every source, opens in the browser and is not sent to the server. All classes · Browse A–Z